Pagoclone

DB04903

small molecule investigational

Deskripsi

Pagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other more well known drugs such as the sleeping medication zopiclone. It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures.

Struktur Molekul 2D

Berat 407.893
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

666 Data
Buprenorphine Pagoclone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pagoclone.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Pagoclone.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Pagoclone.
Hydrocodone Pagoclone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pagoclone.
Magnesium sulfate The therapeutic efficacy of Pagoclone can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Pagoclone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Pagoclone may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pagoclone.
Mirtazapine Pagoclone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Pagoclone.
Orphenadrine Pagoclone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Pagoclone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Pagoclone.
Pramipexole Pagoclone may increase the sedative activities of Pramipexole.
Ropinirole Pagoclone may increase the sedative activities of Ropinirole.
Rotigotine Pagoclone may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Pagoclone.
Suvorexant Pagoclone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pagoclone.
Thalidomide Pagoclone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Pagoclone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Pagoclone.
Sodium oxybate Pagoclone may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Ethanol Pagoclone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Pagoclone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Pagoclone.
Fluvoxamine The risk or severity of adverse effects can be increased when Pagoclone is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Pagoclone is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Pagoclone is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Pagoclone is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Pagoclone is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Pagoclone is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Pagoclone is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Pagoclone is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Pagoclone is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Pagoclone is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Pagoclone is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Pagoclone is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Pagoclone is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Pagoclone is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Pagoclone is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Pagoclone is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Pagoclone is combined with Alaproclate.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Pagoclone.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Pagoclone.
Imipramine The risk or severity of CNS depression can be increased when Imipramine is combined with Pagoclone.
Nortriptyline The risk or severity of CNS depression can be increased when Nortriptyline is combined with Pagoclone.
Amoxapine The risk or severity of CNS depression can be increased when Amoxapine is combined with Pagoclone.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Pagoclone.
Maprotiline The risk or severity of CNS depression can be increased when Maprotiline is combined with Pagoclone.
Doxepin The risk or severity of CNS depression can be increased when Doxepin is combined with Pagoclone.
Desipramine The risk or severity of CNS depression can be increased when Desipramine is combined with Pagoclone.
Pizotifen The risk or severity of CNS depression can be increased when Pagoclone is combined with Pizotifen.
Dosulepin The risk or severity of CNS depression can be increased when Pagoclone is combined with Dosulepin.
Zopiclone The risk or severity of adverse effects can be increased when Pagoclone is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Pagoclone.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Pagoclone.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Pagoclone.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Pagoclone.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Pagoclone.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Pagoclone.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Pagoclone.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Pagoclone.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Pagoclone.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Pagoclone.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Pagoclone.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Pagoclone.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Pagoclone.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Pagoclone.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Pagoclone.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Pagoclone.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Pagoclone.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Pagoclone.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Pagoclone.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Pagoclone.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Pagoclone.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Pagoclone.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Pagoclone.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Pagoclone.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Pagoclone.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Pagoclone.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Pagoclone.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Pagoclone.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Pagoclone.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Pagoclone.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Pagoclone.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Pagoclone.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Pagoclone.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Pagoclone.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Pagoclone.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Pagoclone.
Clozapine The risk or severity of CNS depression can be increased when Clozapine is combined with Pagoclone.
Meprobamate The risk or severity of CNS depression can be increased when Meprobamate is combined with Pagoclone.
Thiethylperazine The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Pagoclone.
Palonosetron The risk or severity of CNS depression can be increased when Palonosetron is combined with Pagoclone.
Sulpiride The risk or severity of CNS depression can be increased when Sulpiride is combined with Pagoclone.
Alprazolam The risk or severity of CNS depression can be increased when Alprazolam is combined with Pagoclone.
Dexbrompheniramine The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Pagoclone.

Target Protein

Gamma-aminobutyric acid receptor subunit gamma-3 GABRG3
Gamma-aminobutyric acid receptor subunit alpha-2 GABRA2
Gamma-aminobutyric acid receptor subunit alpha-3 GABRA3

Referensi & Sumber

Artikel (PubMed)
  • PMID: 16702891
    de Wit H, Vicini L, Haig GM, Hunt T, Feltner D: Evaluation of the abuse potential of pagoclone, a partial GABAA agonist. J Clin Psychopharmacol. 2006 Jun;26(3):268-73.
  • PMID: 16430927
    Atack JR, Pike A, Marshall G, Stanley J, Lincoln R, Cook SM, Lewis RT, Blackaby WP, Goodacre SC, McKernan RM, Dawson GR, Wafford KA, Reynolds DS: The in vivo properties of pagoclone in rat are most likely mediated by 5'-hydroxy pagoclone. Neuropharmacology. 2006 May;50(6):677-89. Epub 2006 Jan 20.
  • PMID: 12625036
    Bateson A: Pagoclone Indevus. Curr Opin Investig Drugs. 2003 Jan;4(1):91-5.
  • PMID: 11565630
    Sandford JJ, Forshall S, Bell C, Argyropoulos S, Rich A, D'Orlando KJ, Gammans RE, Nutt DJ: Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. J Psychopharmacol. 2001 Sep;15(3):205-8.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul